Kiora Pharmaceuticals Inc (KPRX) — Cash Flow-to-Debt Ratio
Kiora Pharmaceuticals Inc (KPRX) has a Cash Flow-to-Debt Ratio of -0.43x as of March 2026, meaning its operating cash flow of $-3.16 Million could theoretically repay 0% of its total liabilities ($7.29 Million) in one year. Check Kiora Pharmaceuticals Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kiora Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Kiora Pharmaceuticals Inc across 14 annual periods. Also explore Kiora Pharmaceuticals Inc balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Kiora Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Kiora Pharmaceuticals Inc. For market capitalisation and broader financial context, see Kiora Pharmaceuticals Inc (KPRX) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.23x | $-9.96 Million | $8.13 Million | ▼ -253.6% |
| 2024 | 0.80x | $8.56 Million | $10.72 Million | ▲ +163.5% |
| 2023 | -1.26x | $-9.56 Million | $7.60 Million | ▲ +12.4% |
| 2022 | -1.43x | $-10.43 Million | $7.27 Million | ▲ +25.4% |
| 2021 | -1.92x | $-10.68 Million | $5.55 Million | ▼ -46.5% |
| 2020 | -1.31x | $-7.32 Million | $5.57 Million | ▲ +43.8% |
| 2019 | -2.34x | $-8.15 Million | $3.49 Million | ▼ -15.1% |
| 2018 | -2.03x | $-10.84 Million | $5.34 Million | ▼ -409.2% |
| 2017 | -0.40x | $-6.47 Million | $16.23 Million | ▲ +52.3% |
| 2016 | -0.84x | $-8.41 Million | $10.06 Million | ▲ +35.8% |
| 2015 | -1.30x | $-4.46 Million | $3.42 Million | ▼ -5581.3% |
| 2014 | -0.02x | $-950.62K | $41.43 Million | ▲ +69.8% |
| 2013 | -0.08x | $-2.96 Million | $38.98 Million | ▲ +46.0% |
| 2012 | -0.14x | $-5.22 Million | $37.16 Million | — |